Goldman Sachs
JBIO

Goldman Sachs’s Jade Biosciences JBIO Stock Holding History

Goldman Sachs’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Buy
735,224
+582,187
+380% +$12.1M ﹤0.01% 2830
2026
Q1 		$2.15M Buy
153,037
+87,697
+134% +$1.27M ﹤0.01% 4471
2025
Q4 		$1.01M Sell
65,340
-97,371
-60% -$1.14M ﹤0.01% 5137
2025
Q3 		$1.4M Buy
+162,711
New +$1.33M ﹤0.01% 4787
2025
Q2 		– Sell
-10,076
Closed -$885K – 6078
2025
Q1 		$885K Buy
10,076
+1,094
+12% +$96.1K ﹤0.01% 4778
2024
Q4 		$833K Buy
8,982
+4,382
+95% +$378K ﹤0.01% 4942
2024
Q3 		$337K Buy
4,600
+2,001
+77% +$129K ﹤0.01% 5251
2024
Q2 		$151K Buy
+2,599
New +$1.72M ﹤0.01% 5332
2022
Q1 		– Sell
-536
Closed -$221K – 6560
2021
Q4 		$221K Buy
+536
New +$271K ﹤0.01% 5838
2021
Q3 		– Sell
-2,993
Closed -$2.39M – 6219
2021
Q2 		$2.39M Buy
+2,993
New +$2.39M ﹤0.01% 4032

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs's JBIO Position: Q2 2026 in Review

Goldman Sachs increased its Jade Biosciences (JBIO) stake by 380% in Q2 2026, buying an estimated $12.1M and bringing the position to 735,224 shares worth $16.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2830.

Goldman Sachs first reported a position in JBIO in Q2 2021 and has held it in 10 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Goldman Sachs held 735,224 shares of Jade Biosciences worth $16.3M as of Q2 2026.
  • Goldman Sachs bought 582,187 Jade Biosciences shares in Q2 2026, an estimated $12.1M.
  • Jade Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2830 holding.
  • Goldman Sachs first reported a position in Jade Biosciences in Q2 2021 and has held it in 10 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.